FindTrial
Sign In

A clinical trial to study the effects of different exercise intensities on an inflammatory marker named C Reactive Protein

Dose Response relationship between Exercise intensity and C Reactive Protein in healthy individuals

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2009/091/001005
Enrollment
92
Registered
2010-02-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Aerobic exercise training: 50-60% of Heart Rate reserve Intervention2: Aerobic exercise training: 60-70% of Heart Rate reserve Intervention3: Aerobic exercise training: 70-80% of Heart

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Individuals of both genders who have not participate in a structured exercise program regularly Plasma CRP value >1mg/L and <10mg/L Aged between 18 to 40 years

Exclusion criteria

Exclusion criteria: Current illness associated with systemic inflammatory response History of hypertension and diabetes Evidence of cardiovascular disease on physical examination, electrocardiography, treadmill exercise testing Cardiovascular medications (including aspirin) / NSAIDs / steroids/ statins/ niacin Any other pulmonary and neuromusculoskeletal impairment that contraindicates exercise Acute illness during the period of study

Design outcomes

Primary

MeasureTime frame
High Sensitivity C reactive ProteinTimepoint: Pre and post exercise training—

Secondary

MeasureTime frame
Peak Oxygen Uptake, Waist Circumference and Percent Body Fat, Body weight, Total Cholesterol, Triglycerides, LDL, HDL, TC/HDL Ratio, Blood glucoseTimepoint: Pre and Post Exercise training—

Countries

India

Contacts

Public ContactFiddy Davis J
fiddydavis@yahoo.com0820 2922533

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026